Results 11 to 20 of about 1,124 (174)
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
BMC Neurology, 2017 Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni +3 more
doaj +2 more sources
Journal of Parkinson’s Disease, 2016 Background: Neurogenic orthostatic hypotension (nOH) is associated with insufficient norepinephrine release in response to postural change. Objective: The objective of this study was to evaluate the long-term safety and durability of efficacy of the ...
Stuart Isaacson +4 more
doaj +2 more sources
Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa [PDF]
Journal of Market Access & Health Policy, 2022 Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
Clément François +5 more
doaj +2 more sources
Neurogenic orthostatic hypotension – management update and role of droxidopa
Therapeutics and Clinical Risk Management, 2015 Joy Vijayan,1 Vijay K Sharma1,21Department of Medicine, Division of Neurology, National University Health System, 2Yong Loo Lin School of Medicine, National University of Singapore, SingaporeAbstract: Orthostatic hypotension (OH) is defined as a ...
Vijayan J, Sharma VK
doaj +1 more source
Droxidopa for Symptomatic Neurogenic Hypotension
Cardiology in Review, 2017 Droxidopa is a first-in-class, orally available, synthetic amino acid precursor of norepinephrine that received accelerated Food and Drug Administration approval in February 2014 after Orphan Drug status for a debilitating condition known as symptomatic neurogenic orthostatic hypotension.
Nadia Ferguson-Myrthil
core +3 more sources
Vascular Health and Risk Management, 2014 Stuart H Isaacson, Julia Skettini Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA Abstract: Neurogenic orthostatic hypotension (nOH) is due to failure of the autonomic nervous system to regulate blood pressure in
Isaacson SH, Skettini J
doaj +1 more source
Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery. [PDF]
Geriatr Gerontol IntGeriatrics &Gerontology International, Volume 25, Issue 12, Page 1962-1964, December 2025.
De Louche CD, Palliyage S.
europepmc +2 more sources
Postprandial Hypotension-Methods for the Evaluation and Management. [PDF]
Geriatr Gerontol IntPostprandial hypotension (PPH) is highly prevalent in older patients; however, its diagnosis remains challenging due to the absence of a consensus guideline for diagnostic criteria. Lifestyle modification is the first‐line management, taking into account the pathophysiology underlying PPH and the coexisting conditions of orthostatic hypotension and ...
Ishikawa J, Toba A, Futami S, Harada K.
europepmc +2 more sources
Neurotransmitter Systems Underlying Freezing of Gait (FOG) in Parkinson's Disease. [PDF]
Eur J NeurosciFreezing of gait (FOG) in Parkinson's disease (PD) arises from dysfunction across multiple neurotransmitter systems within distributed locomotor networks. While dopaminergic deficits contribute to levodopa‐responsive FOG, nondopaminergic systems including cholinergic, noradrenergic, serotonergic, and glutamatergic/GABAergic pathways play key roles in ...
Cho M +7 more
europepmc +2 more sources